Diehl, Frances F.
Miettinen, Teemu P.
Elbashir, Ryan
Nabel, Christopher S.
Darnell, Alicia M.
Do, Brian T.
Manalis, Scott R.
Lewis, Caroline A.
Vander Heiden, Matthew G. http://orcid.org/0000-0002-6702-4192
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (F31CA236036, R01CA201276, P30CA14051, R35CA242379)
Wellcome Trust (110275/Z/15/Z)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (F30HL156404)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32GM007753)
Article History
Received: 21 June 2021
Accepted: 21 June 2022
First Online: 4 August 2022
Change Date: 18 August 2022
Change Type: Update
Change Details: In the version of this article initially published, an incorrect Peer Review File was posted and has now been replaced in the HTML version of the article.
Competing interests
: The authors are aware of no direct conflicts with the topic of the study; however, F.F.D. and M.G.V.H. are included on a patent application regarding impact of nucleotide imbalance on cell state. S.R.M. declares he is a co-founder of Affinity Biosensors and Travera, and M.G.V.H. declares he is an advisory board member for Agios Pharmaceuticals, Aeglea Biotherapeutics, Faeth Therapeutics, Drioa Ventures and iTeos Therapeutics, and a co-founder of Auron Therapeutics. The other authors declare no competing interests.